A view from the access perspective - WHO
Transcript of A view from the access perspective - WHO
![Page 1: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/1.jpg)
The Role of Drug Regulatory AgenciesThe Role of Drug Regulatory AgenciesA view from the access perspectiveA view from the access perspective
Marcel Tanner Christian BurriDirector Head Pharmaceutical Medicine UnitSwiss Tropical Institute, Basel Swiss Tropical Institute, Basel
13th International Conference for Drug Regulatory Authorities - Berne
Friday, September 19th 2008
![Page 2: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/2.jpg)
Agenda
• … the angle of resource limited settings
• Setting the stage• Access & factors influencing access• Current limitations• Forecast workload for DRA• Increasing capacities, maintaining access
• Potential ways forward
![Page 3: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/3.jpg)
Swiss Tropical InstituteSwiss Tropical InstituteBasel, SwitzerlandBasel, Switzerland
![Page 4: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/4.jpg)
Public Health & Epidemiology
Swiss Centre for International Health (SCIH)
Swiss Tropical Institute
ServicesTeachingResearch
Clinical and DiagnosticServices
Medical Parasitology &Infection Biology
Introduction to the Institute
![Page 5: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/5.jpg)
Public Health & Epidemiology
Swiss Centre for International Health (SCIH)
Swiss Tropical Institute
Clinical and DiagnosticServices
Medical Parasitology &Infection Biology
Introduction to the Institute
ApplicationValidation Innovation
![Page 6: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/6.jpg)
Setting the stageDrug regulation ensures thatDrug regulation ensures that……
• Medicines are of the required quality, safety, efficacy
• Health / patients have the necessary information for rational use of medicines
• Medicines are appropriately manufactured, stored, distributed, dispensed
• Illegal manufacturing and trade are detected and adequately sanctioned
• Promotion and adverting is fair, balanced, aimed at rational drug use
• Access to medicines not hindered by unjustified regulatory work
www.who.int/medicines/areas/quality_safety/regulation_legislation/en/
![Page 7: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/7.jpg)
Agenda
• … angle of resource limited settings
• Setting the stage• Access & factors influencing access• Current limitations• Forecast workload for DRA• Increasing capacities, maintaining access
• Potential ways forward
![Page 8: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/8.jpg)
Access to interventionsFactors influencing accessFactors influencing access
• Depending on• Adequate R & D• Diagnosis • Reliable information • Quality of product• Availability• Affordability• Accessibility• Pharmacovigilance
![Page 9: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/9.jpg)
Drug Year Problem
Sleeping sickness
Pentamidine 1939 Limited efficacy against 2nd stage, ADR
Suramin 1920 Limited efficacy against 2nd stage, ADR
Melarsoprol 1949 Most severe ADR, treatment failures
Eflornithine 1980 Difficult application, ADR
Nifurtimox 1970 Not registered, severe ADR
Chagas Disease
Nifurtimox 1970 Long treatment, ADR, limited efficacy against 2nd stage
Benznidazole 1974 Long treatment, ADR, limited efficacy against 2nd stage
Buruli Ulcer
None Surgical intervention necessary
AccessR&D for neglected diseasesR&D for neglected diseases
![Page 10: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/10.jpg)
AccessDiagnosisDiagnosis
GP
![Page 11: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/11.jpg)
CB
AccessReliable informationReliable information
![Page 12: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/12.jpg)
CB
AccessDrug quality
![Page 13: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/13.jpg)
For free is not cheap enoughJ. Jannin, WHO
AccessAccessAvailabilityAvailability
CB
![Page 14: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/14.jpg)
AccessAffordability
Developed by Drug name Price (US $) / adult treatment
Sanofi-Aventis Paluther® (artemether IM) 24.65
GSK Malarone® (atovaquone/proguanil) 12.00
GSK Halfan® (halofantrine) 5.00
Sanofi-Aventis Arsumax® (artesunate) 3.08
Roche Lariam® (mefloquine) 2.60
Novartis Coartem® (artemether/lumefantrine) 2.40
Target price: US$ 1 per adult treatment
MMV-GSK * Artekin® (DHA-piperaquine) ≤1.00
MMV-Shin Poong-Uni Iowa* Pyronaridine/artesunate ≤1.00
DNDi-Sanofi Aventis* Artesunate/amodiaquine ≤1.00
WHO/TDR-GSK Lapdap® (chlorproguanil/dapsone) ≤0.29
Source: Moran 2005, New Landscape of Neglected Disease Drug Development
![Page 15: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/15.jpg)
AccessAccessibilityAccessibility
CB
![Page 16: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/16.jpg)
AccessPharmacovigilancePharmacovigilance
DK
![Page 17: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/17.jpg)
Efficacy
X Access
X Targeting Accuracy
X Provider Compliance
X Consumer Adherence
= Effectiveness
80%
x 80%
x 75%
= 29%
x 80%
X 75%
From Efficacy to Effectiveness
Health System Factors
AccessEfficacy to community effectivenessEfficacy to community effectiveness……
![Page 18: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/18.jpg)
AccessA Health System ProblemA Health System Problem
CB
![Page 19: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/19.jpg)
Agenda
• … angle of resource limited settings
• Setting the stage• Access & factors influencing access• Current limitations• Forecast workload for DRA• Increasing capacities, maintaining access
• Potential ways forward
![Page 20: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/20.jpg)
Today’s approachesFinancial resourcesFinancial resources
• Mix of public funding with fees for services• Government resources very often insufficient• Fees may be a hindrance for drug importation
• Working example: Democratic Republic of Congo• Theoretical annual budget of DRC DRA: US$ 3 mio• Actual financing level: ~10%• Additional income through user fees
• Preliminary approval license 1 yr: US$ 250 tax + 25% fees• License for 5 years: US$ 300 USD tax + 25% fees
Difficult balance between insufficient funding & prohibitive fees in a very fragile market
Source: MPH Thesis T. Barth 2006, STI
![Page 21: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/21.jpg)
Today’s approachesDrug registrationDrug registration
• Working example: Democratic Republic of Congo
• Approach• Authorization of the country of origin required
Country of origin = country of manufacturing
• Capacity• 1 position
• Duration• Between 1 to 3 months w/o fast-track
Source: MPH Thesis T. Barth 2006, STI
![Page 22: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/22.jpg)
Today’s challengesQA &QA & PharmacovigilancePharmacovigilance
• Working example: Democratic Republic of Congo
• Quality Assurance before market entry• Responsibility of the Division Quality Assurance
• Very limited manpower
• Mandated to external (Congolese) laboratories • No independent validation of test results
• Quality assurance after market entry• Task of the Centre of pharmacovigilance• Created in 2003
• Partially operational: 1 coordinator, 1 data manager
• 14 / 5500 MD’s willing to collaborateSource: MPH Thesis T. Barth 2006, STI
![Page 23: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/23.jpg)
Today’s challengesImplementation of rulesImplementation of rules
• Common infringements• Lack of staff qualification• Illegal sales of unpackaged tablets
• Painkillers & antimalarials
• Illegal stocking of prescription only medicines• Lack of information at shop & district-level regulators
• Stocking of unregistered imported drugs• Lack of valid permit• Lack of sanctions
• Private sector needs controlRigorous handling of situation would impede access
Source: Goodman, Health Policy & Planning 1-11
![Page 24: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/24.jpg)
Today’s challengesConduct of clinical trialsConduct of clinical trials
• Authorization to conduct clinical trials• Ethical review largely improved over past 3 years• Trials often conducted without competent review of DRA• Generally no inspections of clinical trials by DRA
Competitive area• DRA has direct impact on attractiveness of country
• Working example Tanzania• Trial stopped by sponsor for safety concerns 14.03.2008• DSMB unblinding & review 02.05.2008, letter to TFDA 15.05.• Clearance to continue enrollment received 25.06.2008• Enrolment complete on 26.06.2008
Difficult initial balance between sufficient control & adequate interference and response
![Page 25: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/25.jpg)
Agenda
• … angle of resource limited settings
• Setting the stage• Access & factors influencing access• Current limitations• Forecast workload for DRA• Increasing capacities, maintaining access
• Potential ways forward
![Page 26: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/26.jpg)
Source: Trouiller et al., Lancet 2002, 359:2188-94
Increasing tasks for DRANew drugs 1975 New drugs 1975 -- 19991999
11393393 new chemical entities marketed
Tropical diseases: 13
Tuberculosis: 3
11.4% of total disease burden1.1% of drugs
![Page 27: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/27.jpg)
Increasing tasks for DRAFunding the new collaborationFunding the new collaboration
Source: Moran 2005, New Landscape of Neglected Disease Drug Development
16%
2%
3%
79%
Philantropic organisations Public sector
Private sector UN agencies0
20
40
60
80
100
120
140
160
2000 2001 2002 2003 2004 2005 2006
In kind (estimated)Total direct R&D spend
PPP direct R&D spend (including projections to 2006)
MMV iOWH TBAlliance
DNDi
US$
M
illio
nen
![Page 28: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/28.jpg)
![Page 29: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/29.jpg)
Increasing tasks for DRAFirst results of the new collaborationFirst results of the new collaboration
Multinationals alone 16
MMV 23
WHO/TDR 6
TB Alliance 9
DNDi 6
iOWH 3
0
10
20
30
40
50
60
70
Active Neglected Disease (ND) drug R&D projects by institution* (Dec 2004)Number of
projects
Source: Moran 2005, New Landscape of Neglected Disease Drug Development
• 63 ND Drug Projects
• 3 new industry ND Institutes
• 18 drug project in clinical trials & 2 ND drugs in registration
• Projection8-9 new drugs until 2010
PPPs
* Medicines for Malaria Venture (MMV), the TB Alliance, Drugs for Neglected Diseases initiative (DNDi) and the institute for One World Health (iOWH)
![Page 30: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/30.jpg)
Increasing tasks for DRAEpidemiological TransitionEpidemiological Transition
Source: World Health Report, 2000
Cause low income countries % Cause developed world %
1 HIV/AIDS 17.9 Ischemic heart disease 22.6
2 Lower respiratory infections 10.1 Cerebrovascular disease 10.7
3 Malaria 9.1 Trachea, bronchus, lung cancers 5.6
4 Diarrheal diseases 6.7 Lower respiratory infections 4.7
5 Perinatal conditions 5.5 Chronic obstructive pulmonary disease
3.5
6 Measles 4.3 Colon and rectum cancers 3.2
7 Tuberculosis 3.6 Diabetes mellitus 2.3
8 Ischemic heart disease 3.1 Stomach cancer 2.0
9 Cerebrovascular disease 2.9 Breast cancer 2.0
10 Road traffic injuries 1.6 Alzheimer and other dementias 1.8
![Page 31: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/31.jpg)
Agenda
• … angle of resource limited settings
• Setting the stage• Access & factors influencing access• Current limitations• Forecast workload for DRA• Increasing capacities, maintaining access
• Potential ways forward
![Page 32: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/32.jpg)
ApproachCollaboration & PartnershipCollaboration & Partnership
A capacity increase at all levels is urgent
It is not necessary that there should exist as many national Pharmacopoeias as there are countries
Same true for pharmaceutical law & National agencies
• 5 non-ICH regions have started harmonization• APEC (Asia – Pacific Economic Cooperation)• ASEAN (Association of South East Asian Nations)• GCC (Gulf Cooperation Council)• PANDRH (Pan-American Network of Drug Regulatory
Harmonization)• SADC (Southern African Development Cooperation)
Source: Participative Conference Health Security Agencies 2007: The global harmonization process in pharmaceuticals; J.L. Valverde
![Page 33: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/33.jpg)
ApproachRegional PartnershipRegional Partnership
• Capacity limitations• Middle income
• Model based on acceptance of foreign marketing licenses• Capacity to assess a generic drug file of national drug industry• Capacity to assess dossier of generic drug with origin in developing country
• Insufficient capacity for data in a registration file for a new drug• Maker / importer of a drug to provide documentation of approval by a
competent / internationally accepted authority• Alternative: product included in WHO prequalification list• Capacity to assess a generic drug file of national drug industry• Capacity to assess dossier of generic drug with origin in developing country
• Countries with very limited financial & technical resources• Responsibility for import of essential drugs delegated to selected
procurement agents• Generic marketing authorization for essential drugs based on published
standard monograph in standard pharmacopeia
Regional collaboration to increase capacitySource: HNP Brief #4, April 2005
![Page 34: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/34.jpg)
ApproachInternational PartnershipInternational Partnership
• Role of WHO• Training, facilitation of information exchange• Expertise• Prequalification procedure
• Role of large drug regulatory agencies• Indirect support
• Transferable priority review vouchers – FDA• Article 58; Scientific advice - EMEA
• Direct support to DRA• Direct support - US offer to Pakistan (20th Aug 2008)• Support to specific R&D programs• Informal advice• Additional, extended meetings
Partnerships welcome & encouraged !
![Page 35: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/35.jpg)
ConclusionsICDRA Recommendations 2006ICDRA Recommendations 2006
• Proactive engagement of small DRAs in international cooperation at regional and global levels
• Adaptation of regulatory system to possibilities• Use of established regulatory pathways• Stepwise development of capacities
Respect & expedite access to essential medicines
• Combat counterfeit and substandard drugs• Information sharing• Control of private market
• Implementation of pharmacovigilance• Focus on medicines approved under special conditions• International collaboration
12th ICDRA Conference - Recommendations
![Page 36: A view from the access perspective - WHO](https://reader030.fdocuments.in/reader030/viewer/2022012020/616887f1d394e9041f704a74/html5/thumbnails/36.jpg)
http://www.sti.ch/